Clinical trials
Kidney Transplant Rejection clinical trials
Below are recruiting kidney transplant rejection clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05600634Recruiting
Monitoring skin graft to spot rejection after kidney transplant
This study follows people after a kidney transplant to see if a small skin graft can help detect early signs of acute rejection. It may help your care team notice rejection sooner and adjust treatment earlier.
Xi'an, ShannxiAges 18–60 - NCT03955172Recruiting
Test of everolimus to reduce transplant rejection
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
LyonAges 18 years+ - NCT06025240Recruiting
Better antibody monitoring after kidney transplant
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
Liverpool, MerseysideAges 18 years+ - NCT07689578RecruitingPhase 4
Testing a new immunotherapy for chronic kidney transplant rejection
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Chengdu, SichuanAges 18 years+ - NCT07663669Recruiting
Photopheresis for antibody-mediated rejection in kidney transplant
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
BesançonAges 18 years+ - NCT07531966Recruiting
Blood Vessel Problems After Kidney Transplant Treatment
This study looks at treating narrowing or blockage of blood vessels in transplanted kidneys. If your transplanted kidney is showing signs of not working well and imaging shows a blocked vessel, this trial tests whether a procedure called angioplasty (opening the vessel with a tiny balloon) can help restore blood flow and improve kidney function.
AarhusAges 18 years+ - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+ - NCT06801262Recruiting
New Blood Test to Detect Kidney Transplant Rejection
This trial is testing a new blood test (called TreaT-Assay) to help diagnose acute rejection after a kidney transplant. The goal is to catch rejection earlier and more accurately, so you can get the right treatment faster.
BolognaAges 18 years+ - NCT07412470RecruitingPhase 2/Phase 3
Testing frexalimab vs tacrolimus for new kidney transplant patients
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
San Francisco, CaliforniaAges 18–70 - NCT07290777RecruitingPhase 2
Study of Vel-101 to prevent kidney transplant rejection
This trial tests a new medicine called VEL-101, which is added to standard anti-rejection drugs, to see if it helps prevent the body from rejecting a new kidney. It is for adults receiving a kidney from a deceased or non-identical living donor.
Dallas, TexasAges 18 years+ - NCT07275541Recruiting
Platelet test for early kidney rejection diagnosis
This study tests whether a simple blood test that looks at platelet behavior can help doctors diagnose acute rejection after a kidney transplant. Early detection of rejection may lead to faster treatment and better outcomes.
MartinAges 18 years+ - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75 - NCT06910527Recruiting
Testing blood and urine for kidney rejection signs
This study is for people with a kidney transplant who are in the hospital for a biopsy because their doctor suspects rejection. Researchers want to see if a simple blood or urine test can detect rejection, which might make future biopsies less necessary.
RouenAges 18 years+ - NCT04702022Recruiting
Extra PET scan to check for silent kidney transplant rejection
This study tests whether an additional PET scan can help detect and guide treatment for “subclinical” (silent) rejection in people with kidney transplants. It may help doctors spot problems earlier and manage them more appropriately.
Liège, LiègeAges 18 years+ - NCT07134491Recruiting
B Cells in Kidney Transplant Rejection Study
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
ParisAges 18 years+ - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT07060716Recruiting
Blood test to monitor kidney transplant health
This study is testing a blood test that looks for tiny pieces of the donor's DNA in your blood to check how your new kidney is doing. It may help doctors monitor your transplant and spot problems early, possibly without needing a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT07053462RecruitingPhase 1/Phase 2
Gene-edited kidney transplant to lower rejection risk
This trial tests a specially edited donor kidney designed to reduce the chance of rejection, especially for people with high sensitivity to donor kidneys. If it works, it could make more kidneys available for those who have a hard time finding a match.
Beijing, ChangpingAges 16–85 - NCT06342128Recruiting
Molecular study of inflammation in kidney transplants
This study looks at molecular changes in kidney transplants that have microvascular inflammation (a type of injury). It aims to better understand why some transplants get this inflammation, which could lead to better treatments.
ParisAges 18–100 - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT05027906RecruitingPhase 1/Phase 2
Study drug AT 1501 for first-time kidney transplant patients
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
Cincinnati, OhioAges 18–100 - NCT06830473Recruiting
Study on predicting kidney transplant rejection in Scotland
This study looks at whether certain tests can help predict or diagnose kidney transplant rejection. If you have had a kidney transplant and are being followed at a main transplant centre in Scotland, you may be able to take part by giving urine samples during your regular check-ups.
EdinburghAges 18–99
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Kidney Transplant Rejection trials by city
Studies with a site in or near these metro areas.
Kidney Transplant Rejection trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for kidney transplant rejection?
- Yes. Clin2 currently lists 80 recruiting kidney transplant rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.